

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

BALB/cNj-Foxn1^{nu}/Gpt

RRID:IMSR_GPT:D000521

Type: Organism

Proper Citation

RRID:IMSR_GPT:D000521

Organism Information

URL: https://en.gempharmatech.com/product/details100035_3907479.html

Proper Citation: RRID:IMSR_GPT:D000521

Description: Mus musculus with name BALB/cNj-Foxn1^{nu}/Gpt from IMSR.

Species: Mus musculus

Notes: gene symbol note: forkhead box N1; mutant strain: Foxn1

Affected Gene: forkhead box N1

Catalog Number: GPT:D000521

Database: GemPharmatech

Database Abbreviation: GPT

Availability: embryo

Organism Name: BALB/cNj-Foxn1^{nu}/Gpt

Record Creation Time: 20250513T053918+0000

Record Last Update: 20260801T050622+0000

Ratings and Alerts

No rating or validation information has been found for BALB/cNj-Foxn1^{nu}/Gpt.

No alerts have been found for BALB/cNj-Foxn1^{nu}/Gpt.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: GemPharmatech

Usage and Citation Metrics

We found 29 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhang Y, et al. (2026) Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. *Cancer cell*, 44(1), 77.

Kong D, et al. (2025) Pp1-87B/PPP1CC-JNK axis integrates apoptosis and ferroptosis-like cell death to regulate cell competition and tumorigenesis. *Cell reports*, 44(9), 116240.

Han P, et al. (2025) Quercetin-derived microbial metabolite DOPAC potentiates CD8+ T cell anti-tumor immunity via NRF2-mediated mitophagy. *Cell metabolism*, 37(12), 2438.

He X, et al. (2025) PI3K?? functions as a protein kinase to promote cellular protein O-GlcNAcylation and acetyl-CoA production for tumor growth. *Molecular cell*, 85(7), 1411.

Gao C, et al. (2025) Hypoxia-induced phase separation of ZHX2 alters chromatin looping to drive cancer metastasis. *Molecular cell*, 85(8), 1525.

Zhou H, et al. (2025) SEL1L confers reduced EMT and drug resistance to breast cancer cells by promoting Shh degradation. *iScience*, 28(11), 113876.

Song Z, et al. (2025) Mechano-oncogenic cytoskeletal remodeling drives leukemic transformation with mitochondrial vesicle-mediated STING activation. *Cell stem cell*, 32(4), 581.

Du M, et al. (2025) CircYAP1 inhibits osteosarcoma progression through the miR-135b-5p/FRK axis. *iScience*, 28(7), 112858.

Xia T, et al. (2025) DDX5 super-enhancer promotes vasculogenic mimicry formation and metastasis in nasopharyngeal carcinoma by enhancing ADAM10 transcription. *Cell reports. Medicine*, 6(6), 102146.

Liu S, et al. (2025) The TIM22 carrier translocase supports cell proliferation by facilitating mitochondrial iron uptake for Fe-S biogenesis. *Molecular cell*, 85(24), 4587.

Cai G, et al. (2025) UMP functions as an endogenous regulator of NR4A1 to control gastric cancer progression. *Molecular cell*, 85(23), 4347.

Hu Q, et al. (2025) circATF6 triggers calcium overload to synergize with EGFR-TKI in non-small cell lung cancer via modulation of proteostasis. *Cell reports*, 44(12), 116659.

Wang N, et al. (2025) Pyruvate metabolism enzyme DLAT promotes tumorigenesis by suppressing leucine catabolism. *Cell metabolism*, 37(6), 1381.

Kwiatkowski N, et al. (2025) CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers. *Cell chemical biology*, 32(4), 556.

Xia Q, et al. (2025) PRMT5-mediated methylation of METTL3 promotes cisplatin resistance in ovarian cancer by facilitating DNA repair mechanisms. *Cell reports*, 44(4), 115484.

Wang P, et al. (2025) Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312. *Cancer research communications*, 5(5), 792.

Song W, et al. (2025) Targeting the UFL1-PARP1 axis amplifies anti-tumor immunity. *Cell reports*, 44(10), 116433.

Ahn DH, et al. (2024) Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(10), 2039.

Wu M, et al. (2024) ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma. *Cell reports*, 43(11), 114962.

Zhang Q, et al. (2024) Decoding sunitinib resistance in ccRCC: Metabolic-reprogramming-induced ABAT and GABAergic system shifts. *iScience*, 27(7), 110415.